Korean Journal of Pediatric Hematology-Oncology  2002;9(2):166-176

Treatment of B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma.

Eun Sil PARK 1 ; Sang Duk KIM ; Hyoung Jin KANG ; Hyoung Soo CHOI ; Hee Young SHIN ; Hyo Seop AHN

Affiliations

+expand

Keywords

B-cell acute lymphoblstic leukemia (B-ALL); B-cell non-Hodgkin's lymphoma; Chemotherapy; Toxic complication

Country

Republic of Korea

Language

Korean

MeSH

Abstract

PURPOSE: We report here the improved survival rate of B-cell acute lymphoblstic leukemia (B-ALL) and B-cell non-Hodgkin's lymphoma (B-NHL) treated with a short, intensive multiagent chemotherapy and the treatment related toxicities and complications. METHODS: From Oct. 1997 to Apr. 2002, 10 patients were enrolled. Patients were classified into three groups (Group A, B, C) according to tumor burden and were treated with CCG 5961, UKCCSG 9600, and LMB96 protocol. Induction chemotherapy included cyclophsophamide, vincristine, prednisolone, doxorubicin and high dose (HD) methotrexate (COPADM). Consolidation chemotherapy included HD methotrexate, HD cytarabine and etoposide (CYM; group B, CYVE; group C). In one patient, HD chemotherapy with stem cell rescue was used because residual disease was detected after consolidation chemotheapy. RESULTS: Four patients were B-ALL and six patients were B-NHL (A; 1, B; 2, C; 7). Regimen was changed in 1 patient because of residual disease (B--